Find that medicines against hepatitis C prevent the duplication of coronavirus

Rio de Janeiro, 25 jun (EFE).- Drugs used for the treatment of hepatitis C and inhibit the duplication of the new coronavirus, SARS-CoV-2 according to the results of a study conducted by the Oswaldo Cruz Foundation (Fiocruz), the largest medical research center of Latin america.

The research, disclosed this Thursday, we evaluated the antiviral sofosbuvir and daclatasvir, with the latter being the one that showed the most potential in the studies against the coronavirus.

“The experiments identified especially the potential of daclatasvir antiviral, which acted against the virus in three different cell lines investigated, in addition to reducing the production of inflammatory substances associated with serious cases of COVID-19,” the report says.

The work was led by the Center for Technological Development in Health of Fiocruz, who reported the finding in the web site preprinted bioRxiv.

In the tests with the COVID-19 daclatasvir interrumipió the synthesis of viral genetic material, which led to the blocking of the duplication of the virus.

In this way, prevented the production of infectious viral particles in three cell lines, including human lung cells.

In defense cells infected, the drug also reduced the production of inflammatory substances, which are associated with hyperinflammation observed in severe cases of the COVID-19.

According to the researchers, the action of daclatasvir on the new coronavirus was more powerful than that of sofosbuvir, because the latter inhibited the duplication of virus in cell lines of liver and lung human, but had no effect during infection in Vero cells, derived from monkey kidney, widely used in studies of virology.

See also  The Leeuwarder Courant uses cookies

The trials also compared the action with the effects of other drugs and noted that the daclastavir was 1.1 to 4 times more efficient than chloroquine and the combination of lopinavir and ritonavir, medicines subject to clinical trials for the treatment of the COVID-19.

The daclatasvir also proved to be more efficient than ribavirin, an antiviral broad-spectrum used in cases of hepatitis.

According to Thiago Moreno, leader of the research, the World Health Organization (WHO) recognizes the repositioning of drugs as the quickest way to identify candidates for treatment with COVID-19.

“Taking into account that the antiviral action directly against the hepatitis C virus are among the safest, our results indicate that these drugs, especially the daclastavir, are candidates for the therapy, with the potential to be incorporated immediately into the clinical trials,” he said.

The scientists have warned about the risks of self-medication, emphasizing that the tests on patients are essential to evaluate the effectiveness of the therapies and that all people with suspected or confirmed cases of the coronavirus should seek medical attention to obtain guidance on the appropriate therapy.

(c) Agencia EFE

Leave a Comment